Technical Data Sheet



Aflibercept Biosimilar - Research Grade ICH4015

Product Information

Catalog Number: ICH4015

Product: Low endotoxin, biosimilar protein

Target: VEGF

Isotype: IgG1

Other names: Vascular endothelial growth factor

Host: Humanized Species Reactivity: Human

Specificity: Detects human VEGF. This non-therapeutic antibody uses the same sequence as the therapeutic antibody

Aflibercept.

Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or

G depending on the species and isotype.

Concentration: 1.0 - 5.0 mg/ml

Formulation: Phosphate buffered saline (PBS) pH 7.2, with no carrier protein, potassium or preservatives added. BSA and

Azide free.

Purity: >95% by SDS-PAGE and HPLC

Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method

Storage: Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working

volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Background:

Aflibercept biosimilar is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration. Aflibercept biosimilar is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of 115 kDa. Aflibercept biosimilar is produced in recombinant Chinese hamster ovary (CHO) cells.